Expected to reach a valuation of US$ 797.8 million by 2033, the global indolent systemic mastocytosis (ISM) treatment market is expected to grow at a CAGR of 6.2% over the forecast period, with a projected market size of US$ 437.4 million in 2023.
Indolent Systemic Mastocytosis is a rare condition characterized by the abnormal accumulation of mast cells in various tissues and organs. The treatment market for ISM has evolved in response to advancements in medical knowledge and the development of therapeutic options.
Historically, treatment options for ISM have been limited. Symptom relief and the avoidance of triggers that activate mast cells have been primary objectives. Supportive care, including the use of antihistamines and medications to manage symptoms such as itching and flushing, formed the foundation of treatment.
Unlock Peak Performance - Get Your Sample Now:
https://www.futuremarketinsights.com/reports/sample/rep-gb-17652
In recent years, there has been a growing focus on research and the development of targeted therapies to address ISM. These advancements are providing hope for improved patient outcomes and better management of this rare condition.
Key Takeaways :
1. Market Growth: The market is expected to experience substantial growth, with a projected valuation of US$ 797.8 million by 2033, driven by a CAGR of 6.2% during the forecast period.
2. Rare Condition: Indolent Systemic Mastocytosis is a rare medical condition characterized by the abnormal accumulation of mast cells in various tissues and organs.
3. Limited Historical Treatments: Historically, treatment options for ISM were limited, focusing on symptom relief and avoiding mast cell activation triggers.
4. Supportive Care: Supportive care played a crucial role in managing ISM, involving the use of antihistamines and medications to address symptoms such as itching and flushing.
5. Advancements in Research: Recent years have witnessed a growing focus on research and the development of targeted therapies for ISM, providing new hope for patients.
6. Improving Patient Outcomes: The emergence of targeted therapies is expected to lead to improved patient outcomes and enhanced management of ISM.
7. Therapeutic Evolution: The treatment market for ISM is evolving, with new therapeutic options and a shift towards more effective and personalized treatments.
8. Patient-Centered Care: The market’s evolution promises to offer tailored solutions for patients affected by ISM, enhancing their overall quality of life.
9. Medical Advancements: Ongoing advancements in medical knowledge are driving progress in understanding and treating this rare condition.
10. Increasing Awareness: Greater awareness and research initiatives are paving the way for more effective treatments and better patient care in the field of ISM.
Key Players :
• AstraZeneca
• Pfizer Inc.
• Mylan N.V.
• Teva Pharmaceuticals
• Novartis
• Blueprint Medicines Corporation
• Merck KgaA
• GSK Plc.
• Deciphera Pharmaceuticals
• Sanofi Aventis
• Eli Lilly & Company
Key Developments:
In May 2023, The USA Food and Drug Administration (FDA) has authorised AYVAKIT® (avapritinib) for the treatment of people with indolent systemic mastocytosis (ISM), according to a statement from Blueprint Medicines Corporation. The first and only medication licenced to treat ISM is now available to all patients in the United States.
Key Segmentation :
By Drug Class:
• Proton-pump Inhibitors
• Omeprazole
• Iasonoprazole
• Mast Cell Stabilizer (Cromolyn Sodium)
• Multikinase Inhibitors
• Midostaurin
• Avapritinib (Ayvakit)
• BCR-ABL tyrosine kinase inhibitors (Imatinib)
• Corticosteroids
• Others Drug Classes
By Drug Type:
• Prescription Drugs
• Over-the-Counter Drugs
By Route of Administration:
• Oral
• Topical
• Parenteral
By Distribution Channel:
• Hospital Pharmacies
• Retail Pharmacies
• Drug Stores
• Online Pharmacies
By Region:
• North America
• Latin America
• Europe
• East Asia
• South Asia
• Oceania
• Middle East & Africa
